ClearPoint Neuro, Inc. (CLPT) Stock Analysis

Research · Aug 25, 2026

Rare-Disease Gene Therapy Shifts From Sham-Surgery Control to Delivery Hardware and Endpoint Instruments

The FDA told uniQure a sham-surgery control is no longer required, moving the cost of rare-disease gene therapy onto delivery hardware and endpoint instruments.

Research · Aug 25, 2026

Rare CNS Gene Therapy Moves Past Sham-Surgery Control

uniQure, ClearPoint and BioCardia disclosed the FDA no longer requires a sham-surgery control in rare CNS gene therapy, moving the gate to delivery hardware.